Jeremy Wingard, MD
Glaucoma Specialist · Wheaton, ILNPI 1124218789
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $32,375 of the $44,527 with a category attached, or 72.7%. AbbVie accounts for 87.5% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2020 at $20,172 and has fallen 99.4% since, to $127 in 2025.
Across 91 payments — averaging $489.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$39K
- Aerie Pharmaceuticals, Inc.$3K
- Carl Zeiss Meditec USA, Inc.$1K
- NEW World Medical,inc.$514
- Alcon$81
- Carl Zeiss Meditec, Inc.$65
- plus $107 from 5 others
What the payments were for
- Consulting fees$6,33314%
- Speaking & faculty fees$32,37573%
- Travel & lodging$2,8376%
- Food & beverage$1,5103%
- Education$800%
- Gifts$450%
- Other$1,3483%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 54 | $38,980 |
| Aerie Pharmaceuticals, Inc. | 7 | $3,432 |
| Carl Zeiss Meditec USA, Inc. | 2 | $1,348 |
| NEW World Medical,inc. | 17 | $514 |
| Alcon | 4 | $81 |
| Carl Zeiss Meditec, Inc. | 1 | $65 |
| Novartis | 2 | $29 |
| Kala Pharmaceuticals, Inc. | 1 | $25 |
| Oyster Point Pharma, Inc. | 1 | $19 |
| Thea Pharma Inc. | 1 | $18 |
| Heidelberg Engineering, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DURYSTA$37,685
- Rocklatan$3,370
- Rhopressa$3,370
- Humphrey Field Analyzer (HFA3)$1,316
- XEN$313
- Kahook Dual Blade$109
- Clearpath$109
- Ahmed Glaucoma Valve$109
- Streamline$109
How this compares
Too few glaucoma specialist providers in Illinoisto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 248 | $140,249 |
| RocklatanNetarsudil Mesylat/Latanoprost | 160 | $115,916 |
| RhopressaNetarsudil Mesylate | 156 | $103,367 |
| CombiganBrimonidine Tartrate/Timolol | 138 | $58,789 |
| Alphagan PBrimonidine Tartrate | 92 | $36,958 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 137 | $28,255 |
| VyzultaLatanoprostene Bunod | 48 | $24,212 |
| Latanoprost | 1,635 | $21,285 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 86 | $21,148 |
| Prednisolone Acetate | 710 | $19,915 |
| Brimonidine Tartrate | 490 | $17,464 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 69 | $16,031 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 973 | $15,787 |
| Brinzolamide | 66 | $13,309 |
| ZioptanTafluprost/Pf | 41 | $13,166 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Combigan, Alphagan P | $38,980 | $235,995478 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $3,432 | $219,282316 claims |
| AlconSimbrinza | $81 | $16,03169 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few glaucoma specialist providers in Illinoison file to place this against a meaningful peer group, so we don't.
Other glaucoma specialist in Wheaton
- Ruth WilliamsWheaton$15K
- Zhuangjun SiWheaton$4K
- Edward SungWheaton$1K
- Frini MakadiaWheaton$833
- Deepak EdwardChicago$53K
- Jessica KangChicago$37K
- David HillmanChicago$10K
- Ayesha BadarMaywood$5K
- Rebecca SarranChicago$3K
- Nandita AnandGlenview$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.